Inhibitor therapeutics inc

Inhibitor Therapeutics, we are a publicly traded, clinical stage pharmaceutical development company. We have a focus on developing and commercializing innovative therapies, using repurposed, already approved API’s (active pharmaceutical ingredients) that have clinical value and are patent protected. We have a significant amount of owned intellectual property around the use of itraconazole in oncology indications, especially in the treatment of Basal Cell Carcinoma Nevus Syndrome and both lung and prostate cancers.

Our Vision is to be recognized as a leading specialty biopharmaceutical company at the forefront of innovation for patients with unmet medical needs. We are committed to restoring health and transforming the lives of patients through development of novel biopharmaceutical products.